Anti-Cd5 Car Nk Cells
T-ALL/Lymphoma
Chongqing Precision Biotech Co., LtdCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
48 Active assets in the T-ALL/Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PREDNISONE TABLETS Children's Oncology Group | Phase 3 | BB |
Cytosin-Arabinosid Princess Maxima Center for Pediatric Oncology | Phase 3 | BB |
Cyclophosphamide Children's Oncology Group | Phase 3 | BB |
ETOPOSIDE Children's Cancer Group, China | Phase 3 | BB |
Daunorubicin Children's Oncology Group | Phase 3 | B |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →